Literature DB >> 32314097

Prognostic value of postoperative C-reactive protein elevation versus complication occurrence: a multicenter validation study.

Yukinori Kurokawa1, Kotaro Yamashita2, Ryohei Kawabata3, Junya Fujita4, Hiroshi Imamura5, Atsushi Takeno6, Tsuyoshi Takahashi2, Makoto Yamasaki2, Hidetoshi Eguchi2, Yuichiro Doki2.   

Abstract

BACKGROUND: Several studies have shown that postoperative complications worsen the prognosis of patients with malignancies. However, our previous study showed that C-reactive protein (CRP) elevation over 12 mg/dL was a more reliable prognostic indicator than complication occurrence. This large-scale, multicenter validation study aimed to confirm the prognostic value of postoperative CRP elevation in resectable gastric cancer.
METHODS: Data of 1456 patients with pT2-T4 gastric cancer who underwent R0 resection were collected from 21 institutions. The prognostic value of the highest postoperative serum level of CRP (CRPmax) during hospitalization was evaluated using the Kaplan-Meier method. The prognostic independence of CRPmax with assessed with a Cox multivariate analysis of recurrence-free survival (RFS).
RESULTS: RFS in the high CRPmax (≥ 12 mg/dL) group was significantly worse than that in the low CRPmax (< 12 mg/dL) group (log-rank P = 0.002). The recurrence pattern showed that liver metastasis occurred more frequently in the high CRPmax group (9.2%) than in the low CRPmax group (4.7%) (P = 0.001). In patients without intra-abdominal infectious complications, the high CRPmax group showed significantly worse RFS than the low CRPmax group (log-rank P = 0.026). In patients with intra-abdominal infectious complications, the high CRPmax group had worse RFS than the low CRPmax group, but this difference was not significant (log-rank P = 0.075). Cox multivariate analysis with 13 covariables showed that CRPmax (P = 0.043) was an independent prognostic factor, but postoperative complications were not (P = 0.387).
CONCLUSION: Postoperative CRP elevation was a better predictor of prognosis in patients with gastric cancer than the occurrence of intra-abdominal infectious complications.

Entities:  

Keywords:  C-reactive protein; Gastrectomy; Gastric cancer; Postoperative complication

Mesh:

Substances:

Year:  2020        PMID: 32314097     DOI: 10.1007/s10120-020-01073-5

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  6 in total

1.  Prognostic significance of the Controlling Nutritional Status (CONUT) score in surgically treated breast cancer patients.

Authors:  Zhang-Zan Huang; Chen-Ge Song; Jia-Jia Huang; Wen Xia; Xi-Wen Bi; Xin Hua; Zhen-Yu He; Zhong-Yu Yuan
Journal:  Gland Surg       Date:  2020-10

2.  Predictive Factors for Acute Postoperative Pain After Open Radical Gastrectomy for Gastric Cancer.

Authors:  Han Xie; Jingxuan Wei; Zhengliang Ma; Weihong Ge
Journal:  Front Public Health       Date:  2022-06-01

3.  Impact of severe postoperative inflammatory response on recurrence after curative resection of colorectal cancer.

Authors:  Yuya Nakamura; Tadayoshi Yamaura; Yousuke Kinjo; Makoto Kawase; Satoshi Kanto; Nobukazu Kuroda
Journal:  Int J Colorectal Dis       Date:  2022-10-24       Impact factor: 2.796

4.  Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer.

Authors:  Gaopeng Li; Guoliang Wang; Fenqing Chi; Yuqi Jia; Xi Wang; Quankai Mu; Keru Qin; Xiaoxia Zhu; Jing Pang; Baixue Xu; Guangen Feng; Yuhu Niu; Tao Gong; Hongwei Zhang; Xiushan Dong; Ting Liu; Jinfeng Ma; Zefeng Gao; Kai Tao; Feng Li; Jun Xu; Baofeng Yu
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

5.  Prognostic impact of postoperative systemic inflammatory response in patients with stage II/III gastric cancer.

Authors:  Kenji Kuroda; Takahiro Toyokawa; Yuichiro Miki; Mami Yoshii; Tatsuro Tamura; Hiroaki Tanaka; Shigeru Lee; Kazuya Muguruma; Masakazu Yashiro; Masaichi Ohira
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

6.  Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer.

Authors:  Feifei Shen; Chuan Liu; Weiguo Zhang; Sijia He; Fan Wang; Jingjue Wang; Qi Li; Fei Zhou
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.